Clinicopathological Characteristics and Prognosis of 35 Cases of Pregnancy-associated Breast Cancer / 肿瘤防治研究

Objective To assess whether pregnancy affects the survival of pregnancy-associated breast cancer (PABC), compared with non-PABC. Methods We retrospectively analyzed the data of PABC patients.PABC cases and non-PABC cases were matched with 1:2 according to T stage, molecular classification, age of onset and year of diagnosis.The Kaplan-Meier method was used to estimate DFS and OS, and Log rank test was used for comparison.Cox regression analysis was used to evaluate the risk factors that affect the prognosis of PABC. Results We enrolled 35 patients in the PABC group (pregnancy: 10;postpartum: 25), and 70 patients in the non-PABC group.The median follow-up time was 68.5 and 70.7 months, respectively.The 5-year DFS was 51.6% in the PABC group, and that of the non-PABC group was 72.8%(χ2=4.72, P=0.029);the 5-year OS of the PABC group and the non-PABC group were similar (χ2=1.769, P=0.183).Cox regression analysis showed that pregnancy was an independent risk factor for DFS of PABC patients (P=0.011). Conclusion Patients with breast cancer during pregnancy have a higher risk of recurrence.Further research is necessary to diagnose pregnancy-associated breast cancer earlier and adopt measures to improve the curative effect.

Clinical analysis of the relationship between liver function damage and hepatitis B virus infection in patients with breast cancer after chemotherapy / 中国生化药物杂志

Objective To investigate the interrelated liver damage and hepatitis B virus infection among breast cancer patients after chemotherapy, to provide guidance for future breast reduction combined hepatitis B virus infection after chemotherapy liver damage.Methods120 cases of breast cancer patients undergoing chemotherapy combined hepatitis B carries from June 2012 to November 2016 in ningbo women and children's hospital were selected as the research object, depending on whether the infection with the hepatitis B virus into the study group and the control group, the study group HBV-DNA, HBsAg are positive, totaling 62 cases;control group, HBV-DNA, HBsAg were negative, totaling 58 cases;compare two groups of patients after chemotherapy in cases of liver damage.ResultsThe study group after chemotherapy, the incidence of liver dysfunction 48.28% in the control group after chemotherapy, the incidence of liver dysfunction 6.45 percent, the study group after chemotherapy, the incidence of liver dysfunction was significantly lower than the control group, the difference was statistically significant (P<0.05).Study group Ⅰ liver damage degree, degree Ⅱ, degree Ⅲ, degree Ⅳ of apparent higher, the difference was statistically significant (P<0.05), antiviral therapy 20 cases, no antiviral treatment in 42 cases.Antiviral therapy HBV reactivation rate and incidence of liver dysfunction were 5.0%, 20.0%;no antiretroviral therapy in HBV reactivation rate and the incidence of liver dysfunction 31.0%, 52.4% respectively;HBV antiviral therapy re-activation rate and the occurrence of liver dysfunction were significantly lower than not antiviral therapy, and the data were statistically significant (P<0.05).ConclusionThe clinical having close links between liver damage and breast cancer combined hepatitis B virus infection with hepatitis B virus are more likely to occur after infection liver dysfunction chemotherapy, and breast cancer patients after chemotherapy.

Enhanced growth inhibition by combined two pathway inhibitors on K-ras mutated non-small cell lung cancer cells / 中华肿瘤杂志

<p><b>OBJECTIVE</b>To evaluate the effect of combined targeting of MEK and PI3K signaling pathways on K-ras mutated non-small cell lung cancer cell line A549 cells and the relevant mechanisms.</p><p><b>METHODS</b>A549 cells were treated with different concentrations of two inhibitors. Growth inhibition was determined by MTT assay. According to the results of MTT test, the cells were divided into four groups: the control group, PI3K inhibitor group (GDC-0941,0.5 and 5.0 µmol/L), combination group I (0.5 µmol/L AZD6244+0.5 µmol/L GDC-0941) and combination group II (5.0 µmol/L AZD6244+5.0 µmol/L GDC-0941). The cell cycle and apoptosis were analyzed by flow cytometry. The expression of proteins related to apoptosis was tested with Western blot.</p><p><b>RESULTS</b>Both GDC-0941 and AZD6244 inhibited the cell proliferation. The combination group II led to a stronger growth inhibition. The combination group I showed an antagonistic effect and combination group II showed an additive or synergistic effect. Compared with the control group, the combination group I led to reduced apoptotic rate [(20.70 ± 0.99)% vs. (18.65 ± 0.92 )%, P > 0.05]; Combination group II exhibited enhanced apoptotic rate [(37.85 ± 3.18)% vs. (52.27 ± 4.36)%, P < 0.01]. In addition, in the combination group II, more A549 cells were arrested in G0/G1 phase and decreased S phase (P < 0.01), due to the reduced expressions of CyclinD1 and Cyclin B1, the increased cleaved PARP and the diminished ratio of Bcl-2/Bax.</p><p><b>CONCLUSIONS</b>For single K-ras mutated NSCLC cell line A549 cells, combination of RAS/MEK/ERK and PI3K/AKT/mTOR inhibition showed synergistic effects depending on the drug doses. Double pathways targeted therapy may be beneficial for these patients.</p>

Venlafaxine vs imipramine, sertraline in treating depression / 中国新药与临床杂志

AIM: To study the clinical efficacy and safety of venlafaxine in the treatment of depression.　METHODS: One hundred and thirty-one patients with depression were randomly divided into 3 groups: venlafaxine group of 43 patients (M23, F20; age 39 a± s 12 a) was treated with venlafaxine, 25-100 mg, po, bid for 6 wk; imipramine group of 43 patients (M 21, F 22; age 38 a±11 a) was treated with imipramine, 25-75 mg,po, bid for 6 wk; sertraline group of 45 patients (M 25, F 20; age 40 a±12 a) was treated with sertraline, 50-100 mg, po, qd for 6 wk.　RESULTS: The total clinical effective retes were 88% for venlafaxine group, 91% for imipramine group and 89% for sertraline group (P>0.05). The adverse reactions in venlafaxine group were lower than that in imipramine group, but were higher than that in sertraline group.　CONCLUSION: Venlafaxine is a safe and effective drug for treatment of depression.

Efficacy of Mirtazapine and Sertraline in the Treatment of Depression with Anxiety Symptoms / 中国心理卫生杂志

0.05) in treating depression symptoms, but the marked effective rate of mirtazapine group and sertraline group were 78.8% and 43.6% (P